• Explore /
  • Poster
  • / A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).

Abstract Poster

Authors

Evan Yu

Evan Y. Yu

University of Washington, Seattle, WA

Evan Y. Yu , David Laidley , Frederic Pouliot , Stephan Probst , Fred Saad , Robert Sabbagh , A. Oliver Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03939689

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS260)

Abstract #

TPS260

Poster Bd #

P4

Abstract Disclosures

Similar Posters

First Author: Evan Y. Yu

First Author: A. Oliver Sartor

First Author: Kim N. Chi

First Author: Matthew Raymond Smith